Press

Awakn Life Sciences Secures Funding to Expand Nordic Commercial Operations

Oct 25 • 3 min read

Awakn Life Sciences Corp. (NEO: AWKN | OTCQB: AWKNF | FSE: 954), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), today announces that its wholly-owned subsidiary Awakn Oslo AS has entered into a debt financing agreement with TD Veen AS , a…

Silo Pharma – Distinctive with Ground-Breaking Research, Commitment to Developing Innovative Solutions

Oct 25 • 2 min read

October 24, 2022 Silo Pharma (NASDAQ: SILO) recently uplisted to the NASDAQ after the exciting progress it made over the last year. “Silo Pharma announced that it had successfully priced its fully underwritten initial public offering, raising gross proceeds of $5 million through the sale of one million shares of common stock,” reads a recent article….

IntelGenx Receives FDA GDUFA Date for Xiromed-Partnered Development Candidate, Buprenorphine Buccal Film

Oct 25 • 3 min read

IntelGenx Corp. (TSX:IGX | OTCQB:IGXT) today announced that its previously undisclosed development candidate, Buprenorphine Buccal Film, for which an abbreviated new drug application (“ANDA”) has been filed by Chemo Research SL (“Chemo”) through its agent and affiliate Xiromed LLC, has received a U.S. Food and Drug Administration Generic Drug User Fee Act (“GDUFA”) date of April…

atai Life Sciences Company, Perception Neuroscience, Completes Enrollment for Phase 2a Clinical Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression

Oct 25 • 4 min read

atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuropsychiatric diseases and its subsidiary, Perception Neuroscience (“Perception”), today announced the completion of enrollment of its Phase 2a clinical trial to evaluate the safety and efficacy of a single intravenous infusion (IV) dose of PCN-101 (R-ketamine). R-ketamine is a stereoisomer of…

Albert Labs provides Corporate Update

Oct 25 • 6 min read

Albert Labs International Corp. (CSE: ABRT) (FSE: VB50), a pharmaceutical drug development company focussed on gaining regulatory approval for active compounds to treat various mental health conditions, has published a corporate update highlighting the progress that has been made since closing its Series A private placement and some information on its future plans and activities. Overview –…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435